JACC:他汀类药物治疗中的“性别歧视”

2018-04-17 MedSci MedSci原创

目前,相比于女性,医生会普遍倾向于男性更应该接受他汀类药物治疗作为心梗的二级预防。本研究的目的旨在评估心梗后接受高强度他汀类药物治疗患者中的性别差异。本研究纳入了MarketScan数据库中16898名(女性占26%)有商业医疗保险的年龄小于65岁的成年人,以及71358名(女性占49%)2014年至2015年年龄≥66岁的心梗出院后接受有他汀类处方药物治疗的患者。分析结果显示,在2014年至20

目前,相比于女性,医生会普遍倾向于男性更应该接受他汀类药物治疗作为心梗的二级预防。本研究的目的旨在评估心梗后接受高强度他汀类药物治疗患者中的性别差异。

本研究纳入了MarketScan数据库中16898名(女性占26%)有商业医疗保险的年龄小于65岁的成年人,以及71358名(女性占49%)2014年至2015年年龄≥66岁的心梗出院后接受有他汀类处方药物治疗的患者。分析结果显示,在2014年至2015年期间,有56%的男性和47%的女性在心梗出院后接受有他汀类药物治疗,接受高强度他汀类药物治疗的女性与男性的调整后风险比为0.91 (95% CI: 0.90-0.92),在事先没有服用他汀类药物治疗的患者中该风险比为0.91 (95% CI: 0.89-0.92),在心梗发生前服用过低或中等强度他汀类药物治疗的患者中分别是0.87 (95% CI: 0.85-0.90)和0.98 (95% CI: 0.97-1.00)。女性整体上来说接受他汀类药物治疗的比例较男性低,在年龄最大和最小的人群中差异最明显。

研究结果显示,在心梗住院后的患者中,女性接受他汀类药物治疗的几率要明显低于男性。

原始出处:

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1854007, encodeId=5ccf185400ef0, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Wed Dec 26 21:57:00 CST 2018, time=2018-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2008905, encodeId=3cda200890518, content=<a href='/topic/show?id=aa4152641d7' target=_blank style='color:#2F92EE;'>#性别歧视#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52641, encryptionId=aa4152641d7, topicName=性别歧视)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=991e83, createdName=wincls, createdTime=Sun Sep 09 18:57:00 CST 2018, time=2018-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2044503, encodeId=6913204450376, content=<a href='/topic/show?id=644725344b1' target=_blank style='color:#2F92EE;'>#他汀类药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25344, encryptionId=644725344b1, topicName=他汀类药)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIibticIBly5jCSic5ZElW4He3rO4DMpUHUFaFX57OicNMnzckWaicBNeStwugWHFCuOdicoakApM4HGmtw/132, createdBy=f8672500006, createdName=ms6390871039024434, createdTime=Sun Mar 03 13:57:00 CST 2019, time=2019-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1325807, encodeId=a17f132580ec2, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Thu Apr 19 06:57:00 CST 2018, time=2018-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1616516, encodeId=62d716165169f, content=<a href='/topic/show?id=51bf6334ec1' target=_blank style='color:#2F92EE;'>#歧视#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63347, encryptionId=51bf6334ec1, topicName=歧视)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e81f19767924, createdName=ms8888626721583891, createdTime=Thu Apr 19 06:57:00 CST 2018, time=2018-04-19, status=1, ipAttribution=)]
    2018-12-26 hbwxf
  2. [GetPortalCommentsPageByObjectIdResponse(id=1854007, encodeId=5ccf185400ef0, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Wed Dec 26 21:57:00 CST 2018, time=2018-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2008905, encodeId=3cda200890518, content=<a href='/topic/show?id=aa4152641d7' target=_blank style='color:#2F92EE;'>#性别歧视#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52641, encryptionId=aa4152641d7, topicName=性别歧视)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=991e83, createdName=wincls, createdTime=Sun Sep 09 18:57:00 CST 2018, time=2018-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2044503, encodeId=6913204450376, content=<a href='/topic/show?id=644725344b1' target=_blank style='color:#2F92EE;'>#他汀类药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25344, encryptionId=644725344b1, topicName=他汀类药)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIibticIBly5jCSic5ZElW4He3rO4DMpUHUFaFX57OicNMnzckWaicBNeStwugWHFCuOdicoakApM4HGmtw/132, createdBy=f8672500006, createdName=ms6390871039024434, createdTime=Sun Mar 03 13:57:00 CST 2019, time=2019-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1325807, encodeId=a17f132580ec2, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Thu Apr 19 06:57:00 CST 2018, time=2018-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1616516, encodeId=62d716165169f, content=<a href='/topic/show?id=51bf6334ec1' target=_blank style='color:#2F92EE;'>#歧视#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63347, encryptionId=51bf6334ec1, topicName=歧视)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e81f19767924, createdName=ms8888626721583891, createdTime=Thu Apr 19 06:57:00 CST 2018, time=2018-04-19, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1854007, encodeId=5ccf185400ef0, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Wed Dec 26 21:57:00 CST 2018, time=2018-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2008905, encodeId=3cda200890518, content=<a href='/topic/show?id=aa4152641d7' target=_blank style='color:#2F92EE;'>#性别歧视#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52641, encryptionId=aa4152641d7, topicName=性别歧视)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=991e83, createdName=wincls, createdTime=Sun Sep 09 18:57:00 CST 2018, time=2018-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2044503, encodeId=6913204450376, content=<a href='/topic/show?id=644725344b1' target=_blank style='color:#2F92EE;'>#他汀类药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25344, encryptionId=644725344b1, topicName=他汀类药)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIibticIBly5jCSic5ZElW4He3rO4DMpUHUFaFX57OicNMnzckWaicBNeStwugWHFCuOdicoakApM4HGmtw/132, createdBy=f8672500006, createdName=ms6390871039024434, createdTime=Sun Mar 03 13:57:00 CST 2019, time=2019-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1325807, encodeId=a17f132580ec2, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Thu Apr 19 06:57:00 CST 2018, time=2018-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1616516, encodeId=62d716165169f, content=<a href='/topic/show?id=51bf6334ec1' target=_blank style='color:#2F92EE;'>#歧视#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63347, encryptionId=51bf6334ec1, topicName=歧视)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e81f19767924, createdName=ms8888626721583891, createdTime=Thu Apr 19 06:57:00 CST 2018, time=2018-04-19, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1854007, encodeId=5ccf185400ef0, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Wed Dec 26 21:57:00 CST 2018, time=2018-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2008905, encodeId=3cda200890518, content=<a href='/topic/show?id=aa4152641d7' target=_blank style='color:#2F92EE;'>#性别歧视#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52641, encryptionId=aa4152641d7, topicName=性别歧视)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=991e83, createdName=wincls, createdTime=Sun Sep 09 18:57:00 CST 2018, time=2018-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2044503, encodeId=6913204450376, content=<a href='/topic/show?id=644725344b1' target=_blank style='color:#2F92EE;'>#他汀类药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25344, encryptionId=644725344b1, topicName=他汀类药)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIibticIBly5jCSic5ZElW4He3rO4DMpUHUFaFX57OicNMnzckWaicBNeStwugWHFCuOdicoakApM4HGmtw/132, createdBy=f8672500006, createdName=ms6390871039024434, createdTime=Sun Mar 03 13:57:00 CST 2019, time=2019-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1325807, encodeId=a17f132580ec2, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Thu Apr 19 06:57:00 CST 2018, time=2018-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1616516, encodeId=62d716165169f, content=<a href='/topic/show?id=51bf6334ec1' target=_blank style='color:#2F92EE;'>#歧视#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63347, encryptionId=51bf6334ec1, topicName=歧视)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e81f19767924, createdName=ms8888626721583891, createdTime=Thu Apr 19 06:57:00 CST 2018, time=2018-04-19, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1854007, encodeId=5ccf185400ef0, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Wed Dec 26 21:57:00 CST 2018, time=2018-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2008905, encodeId=3cda200890518, content=<a href='/topic/show?id=aa4152641d7' target=_blank style='color:#2F92EE;'>#性别歧视#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52641, encryptionId=aa4152641d7, topicName=性别歧视)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=991e83, createdName=wincls, createdTime=Sun Sep 09 18:57:00 CST 2018, time=2018-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2044503, encodeId=6913204450376, content=<a href='/topic/show?id=644725344b1' target=_blank style='color:#2F92EE;'>#他汀类药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25344, encryptionId=644725344b1, topicName=他汀类药)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIibticIBly5jCSic5ZElW4He3rO4DMpUHUFaFX57OicNMnzckWaicBNeStwugWHFCuOdicoakApM4HGmtw/132, createdBy=f8672500006, createdName=ms6390871039024434, createdTime=Sun Mar 03 13:57:00 CST 2019, time=2019-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1325807, encodeId=a17f132580ec2, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Thu Apr 19 06:57:00 CST 2018, time=2018-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1616516, encodeId=62d716165169f, content=<a href='/topic/show?id=51bf6334ec1' target=_blank style='color:#2F92EE;'>#歧视#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63347, encryptionId=51bf6334ec1, topicName=歧视)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e81f19767924, createdName=ms8888626721583891, createdTime=Thu Apr 19 06:57:00 CST 2018, time=2018-04-19, status=1, ipAttribution=)]

相关资讯

Eur Heart J:西地那非不能改善心脏瓣膜置换术后持续性肺动脉高压患者预后

本研究的目的旨在探究西地那非是否能改善心脏瓣膜疾病(VHD)矫正后持续性肺动脉高压患者的预后。本次多中心随机双盲对照临床研究纳入了200名1年前接受过心脏瓣膜置换术且平均肺动脉压力≥30mmHg的成年患者,其中104名患者接受了西地那非治疗,96名患者接受了安慰剂治疗,时间长达6个月,主要终点事件是死亡、心衰入院、功能分级改变和患者自我评估的临床综合评分。分析结果显示,西地那非组仅27名患者的临床

JACC:长QT综合征的风险分层评估体系的建立

长QT综合征(LQTS)是一种常见的遗传性心律失常,常由KCNQ1、KCNH2和SCN5A基因突变导致,该疾病会引起致死性心律失常事件(LAEs)的发生。本研究的目的旨在建立一个风险分级的评估体系,以量化LQTS患者的心律失常发生的风险。本研究纳入了数据库中1710名LQTS患者,平均随访时间是7.1年,对其5年LAEs的发生率进行评估,并评价β受体阻滞剂的抗心律失常效果。分析结果显示,无论LQT

JAHA:青少年的心血管健康状态堪忧

理想心血管健康状态(ICH)是一个较新的概念,本研究的目的旨在评估不同程度肥胖青少年的ICH比例,尤其是严重肥胖青少年中ICH的比例。本横断面研究对300名儿童和青少年进行了ICH的详细评估调查,并根据对象的肥胖程度分为正常体重组、超重组和严重肥胖组。ICH评估体系由7个不同的指标组成,并分为差、中等和良好三个等级。在300个研究对象(平均年龄12.8岁,女性占48%)中,113名为正常体重组,8

盘点:JACC4月第3期研究一览

1. 经导管主动脉瓣置换术数量呈逐年上升趋势DOI: 10.1016/j.jacc.2018.01.079经导管主动脉瓣置换术(TAVR)已经逐渐成为替代外科主动脉瓣置换术(SAVR)的一个选择。本研究纳入了2007年至2015年法国住院数据库中接受AVR治疗的患者,最终共纳入了131251名研究对象:其中SAVR有109317名 (83%),TAVR有21934名 (17%)。AVR数量随时间呈

JACC:体表心电图可作为诊断心肌舒张功能的新手段

心肌松弛功能几乎在所有左室舒张功能不全(LVDD)患者中均有所受损,并且其是心源性和全因死亡率的预测因子。本研究的目的旨在评估体表心电图信号处理(spECG)在诊断心肌松弛功能方面的可行性。本研究纳入了188名门诊行超声心动图检查以诊断LVDD的患者,并对患者进行了12导联spECG检查,通过组织多普勒心超对心肌松弛功能进行确诊。分析结果显示,组织多普勒心超提示有133名(70%)患者出现有心肌松

JAHA:血糖水平与急性卒中患者预后显著相关

本研究的目的旨在探究血糖参数与急性卒中患者临床预后的关系。本研究纳入了急性缺血性卒中和脑出血的患者,在进急诊治疗后的72小时内给患者进行了连续的血糖监测,共记录了八大参数。主要终点事件是3个月的死亡或残疾(改良的Rankin量表评分≥3)。最终,共纳入了58名缺血性卒中患者和42名脑出血患者,血糖的水平在72小时内的变化范围为5.2±1.4 -11.4±3.2 mmol/L,平均血糖水平(OR:1